A group led by Prof. Ke Yang of Peking University Cancer Hospital released real-world evidence evaluating outcomes of minimally invasive esophagectomy (MIE) compared with open esophagectomy (OE) in localised esophageal squamous cell carcinoma (ESCC) patients.
The study, titled “Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer from a Real-World Multicenter Study”, appeared online in Annals of Surgery, one of the top journals in the field.
The multi-site study adopted a real-world cohort design, and conducted a 10-year follow-up in nearly 6000 ESCC patients recruited from two typical high-volume centres in southern and northern China who had undergone either MIE or OE.
By analysing long-term and short-term indicators such as overall survival, postoperative complications and 30/90-day mortality, the study offered high-level evidence on the efficacy and safety of MIE compared with OE in treating ESCC patients.
In addition, the study suggested that MIE could be used as a preferred procedure even for large ESCC tumours (≥ 6 cm).
This finding may expand the indicated population for MIE and facilitate the updating of National Comprehensive Cancer Network (NCCN) guidelines.
The report’s first authors include Associate Fellow Liu Fangfang and Dr. Yang Wenlei from Prof. Ke’s group, as well as their main collaborators from Anyang Cancer Hospital and Cancer Hospital of Shantou University Medical College.
Prof. Ke and Fellow He Zhonghu served as the corresponding authors.
Source: Peking University
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.